NDAORALCAPSULEPriority Review
Approved
Sep 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MILONTIN (phensuximide) is an oral succinimide anticonvulsant approved in 1953 for the treatment of absence seizures. It is a small-molecule CNS agent that suppresses the characteristic 3-Hz spike-and-wave EEG pattern associated with petit mal epilepsy. The drug remains a second-line option in a crowded anticonvulsant market dominated by newer alternatives.
LOE Approaching
With LOE approaching and minimal linked job activity (0 positions), commercial teams supporting MILONTIN are likely small, mature, and focused on maintenance rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MILONTIN offers very limited career advancement opportunities, with zero linked job openings and a product in LOE-approaching stage. Roles supporting this brand are typically small, stable, and focused on maintaining compliance and managing market share erosion rather than building commercial momentum.
Product Manager (Mature Brand)Field Sales Representative
Worked on MILONTIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.